Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 10Leukemia, Myeloid, Acute 9Hodgkin Disease 8Lymphoma, Non-Hodgkin 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Multiple Myeloma 5Lymphoma, Large B-Cell, Diffuse 5Small Cell Lung Carcinoma 4Sarcoma 4Recurrence 4Neuroblastoma 4Central Nervous System Neoplasms 4Lymphoma, T-Cell 3Lymphoma, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Teratoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Optic Nerve Glioma 2Oligodendroglioma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Congenital Abnormalities 2Breast Neoplasms 2

Interventions

Cisplatin 4Pemetrexed 3Etoposide 3Topotecan 2Gemcitabine 2Carboplatin 2vosaroxin 1vinflunine 1veliparib 1taxane 1pomalidomide 1pembrolizumab 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1apalutamide 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Temozolomide 1Radiation 1RRx-001 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Paclitaxel 1Irinotecan 1Histamine Antagonists 1GSK2879552 1Epinephrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Small Cell × etoposide phosphate × Clear all
NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡